Search

ISSN 0959-4973

11. 5-Fluorouracil degradation rate could predict toxicity in stages II–III colorectal cancer patients undergoing adjuvant FOLFOX. Issue 3 (March 2017)

Authors:
Onesti, Concetta E.; Botticelli, Andrea; La Torre, Marco; Borro, Marina; Gentile, Giovanna; Romiti, Adriana; Lionetto, Luana; Petremolo, Antonella; Occhipinti, Mario; Roberto, Michela; Falcone, Rosa; Simmaco, Maurizio; Marchetti, Paolo; Mazzuca, Federica
Journal:
Anti-cancer drugs
Issue:
Volume 28:Issue 3(2017)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

12. 5-Fluorouracil rechallenge after 5-fluorouracil-induced hyperammonemic encephalopathy. Issue 3 (March 2019)

Authors:
Boilève, Alice; Wicker, Camille; Verret, Benjamin; Leroy, Florence; Malka, David; Jozwiak, Mathieu; Pontoizeau, Clément; Ottolenghi, Chris; De Lonlay, Pascale; Ducreux, Michel; Hollebecque, Antoine
Journal:
Anti-cancer drugs
Issue:
Volume 30:Issue 3(2019)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

14. 9-ING-41, a small-molecule glycogen synthase kinase-3 inhibitor, is active in neuroblastoma. Issue 8 (September 2018)

Authors:
Ugolkov, Andrey V.; Bondarenko, Gennadiy I.; Dubrovskyi, Oleksii; Berbegall, Ana P.; Navarro, Samuel; Noguera, Rosa; O'Halloran, Thomas V.; Hendrix, Mary J.; Giles, Francis J.; Mazar, Andrew P.
Journal:
Anti-cancer drugs
Issue:
Volume 29:Issue 8(2018)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

18. A bispecific fusion protein and a bifunctional enediyne-energized fusion protein consisting of TRAIL, EGFR peptide ligand, and apoprotein of lidamycin against EGFR and DR4/5 show potent antitumor activity. Issue 1 (January 2015)

Authors:
Zhu, Daqiang; Wang, Xiaofei; Shang, Yue; Li, Yi; Jiang, Wenguo; Li, Liang; Chen, Shu-zhen
Journal:
Anti-cancer drugs
Issue:
Volume 26:Issue 1(2015)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

19. A bispecific fusion protein and a bifunctional enediyne-energized fusion protein consisting of TRAIL, EGFR peptide ligand, and apoprotein of lidamycin against EGFR and DR4/5 show potent antitumor activity. Issue 1 (January 2015)

Authors:
Zhu, Daqiang; Wang, Xiaofei; Shang, Yue; Li, Yi; Jiang, Wenguo; Li, Liang; Chen, Shu-zhen
Journal:
Anti-cancer drugs
Issue:
Volume 26:Issue 1(2015)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

20. A case of complete response to nivolumab after long-term progression-free survival with tyrosine kinase inhibitor. Issue 9 (October 2018)

Authors:
Mollica, Veronica; Di Nunno, Vincenzo; Corcioni, Beniamino; Fiorentino, Michelangelo; Nobili, Elisabetta; Schiavina, Riccardo; Golfieri, Rita; Brunocilla, Eugenio; Ardizzoni, Andrea; Massari, Francesco
Journal:
Anti-cancer drugs
Issue:
Volume 29:Issue 9(2018)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗